Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...
WASHINGTON (Reuters) - Swiss drugmaker Novartis A said Friday it had won U.S. approval to sell the first once-a-year treatment for the bone-thinning disease osteoporosis. Sign up here. The drug, ...
ZURICH, April 17 (Reuters) - Swiss drugmaker Novartis has received approval in the United States for its Reclast drug as a treatment for Paget's disease of the bone, the company said on Tuesday.
Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results